The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases
Podcast Description
AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.
Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.
Podcast Insights
Content Themes
The podcast centers on neurodegenerative diseases, particularly Alzheimer's and Parkinson's, covering areas like regulatory philosophies, approval processes, biomarker developments, and clinical implications. Recent episodes discuss topics such as varying regulatory approaches to drug approvals across different regions and the role of biomarkers in treatment selection, reflecting the latest research presented at the AD/PD™ 2025 Conference.

AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. The “AD/PD™ Session Spotlight” series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.
Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.
In this episode, we highlight Plenary Lecture 05 from the AD/PD™ 2025 International Conference — “Pathogenic Mechanisms of Familial AD and Emerging Therapeutic Developments.”
Chaired by Prof. Manfred Windisch (Austria), the lecture was delivered by Prof. Jie Shen (USA), a leading neurologist from Harvard Medical School whose pioneering research has transformed our understanding of familial Alzheimer’s disease (FAD) and its underlying molecular mechanisms.
Key highlights include:
• The Preclin hypothesis: how loss of presenilin function drives neurodegeneration and dementia in AD• Insights into presenilin mutations as loss-of-function drivers impacting synaptic activity, memory, and neuronal survival• Preclinical evidence supporting presenilin-based gene therapy as a potential treatment for familial AD• The role of lipid homeostasis genes interacting with presenilin as modulators of neurodegeneration• How restoring wild-type presenilin function in mouse models rescues gamma-secretase activity and reverses memory deficits• The broader implications of presenilin and APP mutations for both mechanistic understanding and future therapies
This lecture is particularly relevant for neuroscientists, geneticists, translational researchers, and drug developers interested in the molecular underpinnings of Alzheimer’s disease and next-generation therapeutic strategies.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.